BRIEF-Urogen Pharma Ltd - Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial

May 13 (Reuters) - Urogen Pharma Ltd UR8.F:

  • UROGEN PHARMA LTD - REPORTS 36-MONTH DURATION OF RESPONSE OF 64.5% FOR ZUSDURI IN PHASE 3 ENVISION TRIAL

  • UROGEN PHARMA LTD - MEDIAN DURATION OF RESPONSE NOT REACHED AT 35.5 MONTHS FOLLOW-UP

  • UROGEN PHARMA LTD - SERIOUS ADVERSE REACTIONS OCCURRED IN 12% OF PATIENTS IN ENVISION TRIAL

Source text: ID:nGNX5Rj2py

Further company coverage: UR8.F


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.